Director, Program Management
Keros Therapeutics
Director, Program Management
Keros Therapeutics
Develops TGF-ß signaling-modulating therapeutics
At Keros, our mission is to deliver significant clinical benefit to a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. With a focus on developing differentiated product candidates that are designed to alter TGF-β signaling, we aim to target the pathways critical for the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. We believe our product candidates have the potential to unlock the full therapeutic benefits of modulating the TGF-β superfamily and provide disease-modifying benefit to patients.
Job Summary
The Director, Program Management, will provide strategic and operational leadership for the rinvatercept (KER-065) development program. This individual will lead cross-functional program planning and execution as rinvatercept advances through clinical development. The ideal candidate will combine strong drug-development program leadership with meaningful experience running clinical trials across Phase 1, Phase 2 and Phase 3.
The successful candidate will move effectively between strategic planning and hands-on execution, anticipate and mitigate risks, drive timely decisions and maintain alignment across Clinical Development, Clinical Operations, Regulatory Affairs, CMC/Technical Operations, Nonclinical, Biometrics and other functions.
Primary Responsibilities
Program Strategy and Leadership
Integrated Development Planning
Clinical Development and Trial Execution
Cross-Functional Team Effectiveness
Governance and Decision-Making
Risk, Issue and Dependency Management
Executive and External Communication
Program Operations, Budget and Resources
Core Competencies (Required Skills)
Preferred Skills
Education Requirements
This pay range represents the base hourly rate or base annual full-time salary for all positions in the job grade within which this position falls. The actual base salary offer will depend on a variety of factors including experience, education, and other relevant factors.
Our Diversity, Equity & Inclusion Mission Statement:Keros is an inclusive company. We believe that diversity drives innovation. We continue to build an inclusive culture that encourages, supports, and celebrates the diverse voices of our employees. As such, Keros takes a holistic approach in mentoring, coaching, and developing all of our Keros team members.
Keros Therapeutics is an Equal Opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected veteran status, or any other characteristic protected by applicable federal, state, or local law.
Recruitment & Staffing Agencies:
Keros Therapeutics does not accept unsolicited resumes from any source other than the candidate directly. Any unsolicited submission by an agency to Keros is prohibited. Any resume submitted by an agency without a signed contract or expressed consent by a member of the Keros Therapeutics Human Resources Department, will be considered property of Keros Therapeutics, and no fee shall be owed with respect thereto.
Potential base pay range 201000 - 239000 USD
Develops TGF-ß signaling-modulating therapeutics
Keros Therapeutics focuses on developing therapies that target the transforming growth factor-beta (TGF-ß) signaling pathway to treat diseases linked to its dysfunction. Its products aim to modulate TGF-ß signaling to influence cellular growth and repair, with the goal of altering disease progression and providing disease-modifying benefits, especially in blood cells and tissues. The company advances therapeutics through research and development, with commercialization as its end goal once therapies are approved for patients. What sets Keros apart is its specialized expertise in TGF-ß biology and its emphasis on creating drugs that directly modulate this signaling network to produce meaningful clinical outcomes. The overall goal is to bring therapies to market that improve patient outcomes by correcting or adjusting TGF-ß-related signaling in relevant diseases.
Explore more opportunities at Keros Therapeutics